KemPharma Balance Sheet - Quarterly (NASDAQ:KMPH)

Add to My Stocks
$4.85 $0.3 (5.83%) KMPH stock closing price Sep 17, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our KemPharma stock analysis. All three financial statements should be used to measure the financial performance of the company, and should form a part of the KemPharma stock analysis. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. KemPharma had a long term debt of $- at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at KemPharma operating cash flow and KemPharma revenue also. KemPharma debt to equity ratio is .

View and download KemPharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Cash17.6M9.85M11.97M8.92M13.48M13.98M17.86M21.94M28.61M77.33M
Marketable Securities11.7M25.87M31.35M37.41M41.1M48.24M51M42.67M55.13M33.66M
Receivables-1.51M2M2.5M--5M---
Inventory----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.61M1.84M1.66M1.35M------
Total Current Assets
30.91M39.07M46.99M50.19M55.36M63.01M74.35M65.26M84.56M111.38M
Property Plant & Equipment--2.93M---2.57M---
Accumulated Depreciation----------
Net Property Plant & Equipment
1.84M1.92M2M2.08M2.14M2.2M1.97M1.45M1.1M-
Investment & Advances--3.25M6.71M11.21M10.16M8.2M27.35M18.85M-
Other Non-Current Assets----------
Deferred Charges----------
Intangibles----------
Deposits & Other Assets1.25M1.64M--------
Total Assets
34M42.64M52.45M59.31M69.04M75.64M84.88M94.54M104.63M111.93M
Notes Payable3.33M3.33M3.33M1.36M-3.84M----
Accounts Payable13.97M10.17M7.87M6.35M6.3M4.58M6.44M5.59M5.35M4.17M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses----------
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
17.6M13.81M11.5M6.64M6.59M4.8M6.64M5.7M7.39M5.84M
Mortgages----------
Deferred Taxes/Income----------
Convertible Debt86.85M89.78M89.39M92.34M91.95M91.56M91.17M90.77M90.38M90.08M
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities12.63M18.21M8.5M8.42M9.78M13.2M5.77M7.86M6.52M27.49M
Total Liabilities
117.55M122.33M109.97M107.41M108.32M109.57M103.58M104.34M104.3M123.42M
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus117.39M111.26M107.2M106.05M104.9M103.73M102.64M101.6M98.32M96.27M
Retained Earnings-200.94M-190.94M-164.72M-154.16M-144.17M-137.66M-121.34M-111.4M-97.99M-107.75M
Treasury Stock----------
Other Liabilities----------
Shareholders Equity-83.55M-79.68M-57.51M-48.1M-39.27M-33.92M-18.69M-9.8M--11.48M
Total Liabilities & Shareholders Equity34M42.64M52.45M59.31M69.04M75.64M84.88M94.54M104.63M111.93M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The latest KemPharma stock price, and KemPharma historical stock prices show the stock price movement over time, and the KemPharma PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: KMPH total assets, which was at $34M for 2018 Q2 is a balance sheet item representing value of what KemPharma owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. KMPH stock had total liabilities of $117.55M for the quarter 2018 Q2.

KemPharma Balance Sheet - Key Ratios